ライフサイエンスコーパス: Janus kinase 1

1 RS-1 renders it a poorer substrate for JAK1 (Janus kinase-1).

2 facitinib (CP-690,550), an oral inhibitor of Janus kinases 1, 2, and 3 with in vitro functional speci

3 ase 2 study for the treatment of MF with the Janus kinase 1/2 (JAK1/2) inhibitor momelotinib (MMB) de

4 The development of the dual Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib for the

5 Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evol

6 agues report their results on the use of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib in murin

7 a STAT3/5 inhibitor, or with ruxolitinib, a Janus kinase 1/2 (JAK1/2) inhibitor.

8 Recently, several Janus kinase 1/2 (JAK1/2) inhibitors, such as ruxolitini

9 ) transcription factor and the JAK1/2-STAT3 (Janus Kinase 1/2 - Signal Transducer and Activator of Tr

10 n of STAT1 signaling with the small-molecule Janus kinase 1/2 inhibitor ruxolitinib in vitro and in v

11 Treatment with the Janus kinase 1/2 inhibitor ruxolitinib reduced hyperresp

12 was abrogated by ex vivo treatment with the janus kinase 1/2 inhibitor ruxolitinib.

13 to dexamethasone and INCB018424, a selective Janus kinase 1/2 inhibitor.

14 dogenously processed K(d)-restricted peptide Janus kinase-1(3)(5)(5)(-)(3)(6)(3) (~15,000 copies/cell

15 The Janus kinase 1/3 inhibitor R507 is a very well-tolerated

16 The efficacy of selective Janus kinase 1/3 inhibitor R507 to prevent obliterative

17 treatment with tofacitinib citrate, an oral Janus kinase 1/3 inhibitor, resulted in significant repi

18 validation of one of these candidates, Jak1 (Janus kinase 1), a tyrosine kinase of the nonreceptor ty

19 In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced disease activity

20 helial cells by decreasing the expression of Janus kinase 1 and p48, two essential components of the

21 ptor and correlated with rapid and sustained Janus kinase 1 and tyrosine kinase (Tyk) 2 tyrosine phos

22 mmac-dependent signal requires activation of Janus kinases 1 and 3 and is sensitive to wortmannin, im

23 s found that IL-4-induced phosphorylation of Janus kinases 1 and 3, IL-4R alpha, signal transducer an

24 eceptor 2/beta-chain of the receptor, STAT1, Janus kinase 1, and tyrosine kinase 2.

25 so did not cause disassociation of the gp130-janus kinase-1 complex.

26 The Janus kinase-1-deficient cell line U4A expresses HLA-DR

27 nt inhibition of interleukin-6 activation of janus kinase-1, gp 130, the interleukin-6 receptor, STAT

28 e interleukin-6 signaling pathway, including janus kinase-1, gp 130, the interleukin-6 receptor, STAT

29 Finally, we determined that inhibition of Janus kinase 1, inhibition of Glycogen synthase kinase 3

30 d that phosphorylation levels of IL-4Ralpha, Janus kinase 1, insulin receptor substrate 1, and insuli

31 e intracellular domain of IL-4Ralpha induces Janus kinase 1 (Jak1) activation, STAT6 activation, and

32 we discovered that miR-373 directly targets Janus kinase 1 (JAK1) and IFN-regulating factor 9 (IRF9)

33 INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.

34 Furthermore, Janus kinase 1 (jak1) and Jak2 protein tyrosine kinases

35 PDGF stimulates tyrosine phosphorylation of Janus kinase 1 (JAK1) and the signal transducer and acti

36 reventing the accumulation of phosphorylated Janus kinase 1 (JAK1) and tyrosine kinase 2 (Tyk2).

37 ng the IL-4Ralpha subunit and the associated Janus kinase 1 (Jak1) as common essential components.

38 f the FERM and SH2-like domains of the human Janus kinase 1 (JAK1) bound to a fragment of the intrace

39 is required for H(2)O(2) responsiveness, and Janus kinase 1 (JAK1) is required for adequate basal sig

40 to be associated with a striking decrease in Janus kinase 1 (Jak1) levels.

41 enes encoding interferon-receptor-associated Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), concurre

42 mutations, including activating mutations of Janus kinase 1 (JAK1), in 9.1% of patients and provides

43 ng the IL-2 receptor beta chain (IL-2Rbeta), Janus kinase 1 (Jak1), Jak3, signal transducer/activator

44 ctivators of transcription 1 (STAT1), STAT3, Janus kinase 1 (Jak1), Shc, Grb2, Sos1, and HGF receptor

45 eron (IFN) signaling antagonist by targeting Janus kinase 1 (JAK1).

46 main-containing protein (RLTPR); moesin; and Janus kinase 1 (JAK1).

47 IFN-gamma alone can activate NF-kappaB, by a Janus kinase-1-mediated, but Stat1-independent, mechanis

48 nt mutations of either the Box1 motif (binds Janus kinase 1) or the signal transducer and activator o

49 10 (IP-10), and the signaling intermediates Janus kinase 1, signal transducer and activator of trans

50 Expression of the activated form of Janus kinase 1 supported a role for IL-10 in prosurvival

51 rc, epidermal growth factor receptor (EGFR), Janus kinase 1, tyrosine kinases, and G-protein-coupled

52 mponent of IL-6 signal transduction pathway, janus kinase-1, was unchanged following either CLP or 2C